Literature DB >> 19210747

EPAC proteins transduce diverse cellular actions of cAMP.

Gillian Borland1, Brian O Smith, Stephen J Yarwood.   

Abstract

It has now been over 10 years since efforts to completely understand the signalling actions of cAMP (3'-5'-cyclic adenosine monophosphate) led to the discovery of exchange protein directly activated by cAMP (EPAC) proteins. In the current review we will highlight important advances in the understanding of EPAC structure and function and demonstrate that EPAC proteins mediate multiple actions of cAMP in cells, revealing future targets for pharmaceutical intervention. It has been known for some time that drugs that elevate intracellular cAMP levels have proven therapeutic benefit for diseases ranging from depression to inflammation. The challenge now is to determine which of these positive actions of cAMP involve activation of EPAC-regulated signal transduction pathways. EPACs are specific guanine nucleotide exchange factors for the Ras GTPase homologues, Rap1 and Rap2, which they activate independently of the classical routes for cAMP signalling, cyclic nucleotide-gated ion channels and protein kinase A. Rather, EPAC activation is triggered by internal conformational changes induced by direct interaction with cAMP. Leading from this has been the development of EPAC-specific agonists, which has helped to delineate numerous cellular actions of cAMP that rely on subsequent activation of EPAC. These include regulation of exocytosis and the control of cell adhesion, growth, division and differentiation. Recent work also implicates EPAC in the regulation of anti-inflammatory signalling in the vascular endothelium, namely negative regulation of pro-inflammatory cytokine signalling and positive support of barrier function. Further elucidation of these important signalling mechanisms will no doubt support the development of the next generation of anti-inflammatory drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19210747      PMCID: PMC2795248          DOI: 10.1111/j.1476-5381.2008.00087.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  185 in total

1.  Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs.

Authors:  J de Rooij; H Rehmann; M van Triest; R H Cool; A Wittinghofer; J L Bos
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

2.  Epac1 regulates integrity of endothelial cell junctions through VE-cadherin.

Authors:  Matthijs R H Kooistra; Monica Corada; Elisabetta Dejana; Johannes L Bos
Journal:  FEBS Lett       Date:  2005-09-12       Impact factor: 4.124

Review 3.  PKA-dependent and PKA-independent pathways for cAMP-regulated exocytosis.

Authors:  Susumu Seino; Tadao Shibasaki
Journal:  Physiol Rev       Date:  2005-10       Impact factor: 37.312

Review 4.  Regulation of immune cell adhesion and migration by regulator of adhesion and cell polarization enriched in lymphoid tissues.

Authors:  Tatsuo Kinashi; Koko Katagiri
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

5.  Elevation of cyclic AMP in Jurkat T-cells provokes distinct transcriptional responses through the protein kinase A (PKA) and exchange protein activated by cyclic AMP (EPAC) pathways.

Authors:  Suzanne Fuld; Gillian Borland; Stephen J Yarwood
Journal:  Exp Cell Res       Date:  2005-09-10       Impact factor: 3.905

6.  Epac activation converts cAMP from a proliferative into a differentiation signal in PC12 cells.

Authors:  Simone Kiermayer; Ricardo M Biondi; Jochen Imig; Guido Plotz; Jörg Haupenthal; Stefan Zeuzem; Albrecht Piiper
Journal:  Mol Biol Cell       Date:  2005-10-05       Impact factor: 4.138

7.  cAMP increases Ca2+-dependent exocytosis through both PKA and Epac2 in mouse melanotrophs from pituitary tissue slices.

Authors:  Simon Sedej; Tobias Rose; Marjan Rupnik
Journal:  J Physiol       Date:  2005-06-30       Impact factor: 5.182

8.  The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways.

Authors:  Kimberly L Dodge-Kafka; Joseph Soughayer; Genevieve C Pare; Jennifer J Carlisle Michel; Lorene K Langeberg; Michael S Kapiloff; John D Scott
Journal:  Nature       Date:  2005-09-22       Impact factor: 49.962

Review 9.  Keynote review: phosphodiesterase-4 as a therapeutic target.

Authors:  Miles D Houslay; Peter Schafer; Kam Y J Zhang
Journal:  Drug Discov Today       Date:  2005-11-15       Impact factor: 7.851

10.  Specific integrin alpha and beta chain phosphorylations regulate LFA-1 activation through affinity-dependent and -independent mechanisms.

Authors:  Susanna C Fagerholm; Tiina J Hilden; Susanna M Nurmi; Carl G Gahmberg
Journal:  J Cell Biol       Date:  2005-11-21       Impact factor: 10.539

View more
  59 in total

Review 1.  Regulation of the inflammatory response of vascular endothelial cells by EPAC1.

Authors:  Euan Parnell; Brian O Smith; Timothy M Palmer; Anna Terrin; Manuela Zaccolo; Stephen J Yarwood
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  ACTH induces Cav3.2 current and mRNA by cAMP-dependent and cAMP-independent mechanisms.

Authors:  Haiyan Liu; Judith A Enyeart; John J Enyeart
Journal:  J Biol Chem       Date:  2010-04-27       Impact factor: 5.157

4.  Protein kinase A acts at the basal body of the primary cilium to prevent Gli2 activation and ventralization of the mouse neural tube.

Authors:  Miquel Tuson; Mu He; Kathryn V Anderson
Journal:  Development       Date:  2011-10-17       Impact factor: 6.868

5.  The fundamental unit of pain is the cell.

Authors:  David B Reichling; Paul G Green; Jon D Levine
Journal:  Pain       Date:  2013-12       Impact factor: 6.961

6.  GPCR theme editorial.

Authors:  G Milligan; J C McGrath
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

Review 7.  The adenylyl cyclase activity of anthrax edema factor.

Authors:  Wei-Jen Tang; Qing Guo
Journal:  Mol Aspects Med       Date:  2009-06-26

8.  Rap1GAP impairs cell-matrix adhesion in the absence of effects on cell-cell adhesion.

Authors:  Lisa A Vuchak; Oxana M Tsygankova; Judy L Meinkoth
Journal:  Cell Adh Migr       Date:  2011-07-01       Impact factor: 3.405

9.  Type 10 soluble adenylyl cyclase is overexpressed in prostate carcinoma and controls proliferation of prostate cancer cells.

Authors:  Jan-Paul Flacke; Hanna Flacke; Avinash Appukuttan; Rein-Jüri Palisaar; Joachim Noldus; Brian D Robinson; H Peter Reusch; Jonathan H Zippin; Yury Ladilov
Journal:  J Biol Chem       Date:  2012-12-19       Impact factor: 5.157

10.  PKA and Epac cooperate to augment bradykinin-induced interleukin-8 release from human airway smooth muscle cells.

Authors:  Sara S Roscioni; Loes E M Kistemaker; Mark H Menzen; Carolina R S Elzinga; Reinoud Gosens; Andrew J Halayko; Herman Meurs; Martina Schmidt
Journal:  Respir Res       Date:  2009-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.